Ketogenic diet for mitochondrial disease: a systematic review on efficacy and safety

Orphanet Journal of Rare Diseases

Annemiek M. J. van Wegberg¹  Heidi Zweers¹  Mirian C. H. Janssen²  Saskia B. Wortmann³ 

[1] Department of Gastroenterology and Hepatology - Dietetics, Radboudumc, Postbus 9101, 6500 HB, Nijmegen, The Netherlands;Radboud Center for Mitochondrial Medicine (RCMM), Amalia Children’s Hospital, Radboudumc, Nijmegen, The Netherlands;Radboud Center for Mitochondrial Medicine (RCMM), Amalia Children’s Hospital, Radboudumc, Nijmegen, The Netherlands;Department of Internal Medicine, Radboudumc, Nijmegen, The Netherlands;Radboud Center for Mitochondrial Medicine (RCMM), Amalia Children’s Hospital, Radboudumc, Nijmegen, The Netherlands;University Children’s Hospital, Paracelsus Medical University, Salzburg, Austria;

关键词: Epilepsy;    Complex I;    Treatment;    Management;    Mitochondrial myopathy;    OXPHOS;    Mitochondrial DNA deletion;    Adverse event;    Modified Atkins diet;    High fat diet;   

DOI  :  10.1186/s13023-021-01927-w

来源: Springer

【 摘 要 】

BackgroundNo curative therapy for mitochondrial disease (MD) exists, prioritizing supportive treatment for symptom relief. In animal and cell models ketones decrease oxidative stress, increase antioxidants and scavenge free radicals, putting ketogenic diets (KDs) on the list of management options for MD. Furthermore, KDs are well-known, safe and effective treatments for epilepsy, a frequent symptom of MD. This systematic review evaluates efficacy and safety of KD for MD.MethodsWe searched Pubmed, Cochrane, Embase and Cinahl (November 2020) with search terms linked to MD and KD. From the identified records, we excluded studies on Pyruvate Dehydrogenase Complex deficiency. From these eligible reports, cases without a genetically confirmed diagnosis and cases without sufficient data on KD and clinical course were excluded. The remaining studies were included in the qualitative analysis.ResultsOnly 20 cases (14 pediatric) from the 694 papers identified met the inclusion criteria (one controlled trial (n = 5), 15 case reports). KD led to seizure control in 7 out of 8 cases and improved muscular symptoms in 3 of 10 individuals. In 4 of 20 cases KD reversed the clinical phenotype (e.g. cardiomyopathy, movement disorder). In 5 adults with mitochondrial DNA deletion(s) related myopathy rhabdomyolysis led to cessation of KD. Three individuals with POLG mutations died while being on KD, however, their survival was not different compared to individuals with POLG mutations without KD.ConclusionData on efficacy and safety of KD for MD is too scarce for general recommendations. KD should be considered in individuals with MD and therapy refractory epilepsy, while KD is contraindicated in mitochondrial DNA deletion(s) related myopathy. When considering KD for MD the high rate of adverse effects should be taken into account, but also spectacular improvements in individual cases. KD is a highly individual management option in this fragile patient group and requires an experienced team. To increase knowledge on this—individually—promising management option more (prospective) studies using adequate outcome measures are crucial.

【 授权许可】

CC BY